|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study显示文摘This study aimed to evaluate the efficacy of Chinese herbal medicine(CHM)in patients with severe/critical coronavirus disease 2019(COVID-19).In this retrospective study,data were collected from 662 patients with severe/critical COVID-19 who were admitted to a designated hospital to treat patients with severe COVID-19 in Wuhan before March 20,2020.All patients were divided into an exposed group(CHM users)and a control group(non-users).After propensity score matching in a 1:1 ratio,156 CHM users were matched by propensity score to 156 non-users.No significant differences in seven baseline clinical variables were found between the two groups of patients.All-cause mortality was reported in 13 CHM users who died and 36 non-users who died.After multivariate adjustment,the mortality risk of CHM users was reduced by 82.2%(odds ratio 0.178,95%CI 0.076–0.418;P<0.001)compared with the non-users.Secondly,age(odds ratio 1.053,95%CI 1.023–1.084;P<0.001)and the proportion of severe/critical patients(odds ratio 0.063,95%CI 0.028–0.143;P<0.001)were the risk factors of mortality.These results show that the use of CHM may reduce the mortality of patients with severe/critical COVID-19. | Guohua Chen Wen Su Jiayao Yang Dan Luo Ping Xia Wen Jia Xiuyang Li Chuan Wang Suping Lang Qingbin Meng Ying Zhang Yuhe Ke An Fan Shuo Yang Yujiao Zheng Xuepeng Fan Jie Qiao Fengmei Lian Li Wei Xiaolin Tong | 2020 | Frontiers of Medicine2020，14，6： | 10 |
| 2 | Efficacy of Shenzhuo formula on diabetic kidney disease:a retrospective study显示文摘OBJECTIVE:To observe the efficacy of a traditional Chinese medicine,Shenzhuo formula,on patients with diabetic kidney disease(DKD).METHODS:Eighty-eight outpatients with DKD were enrolled.Changes in estimated glomerular filtration rate(eGFR),creatinine clearance,serum creatinine,blood-urea-nitrogen,albuminuria,glycosylated hemoglobin(Hb_(A1C)),blood pressure,and lipid profile were measured and analyzed before and after intervention with Shenzhuo formula for 1,3,6,9,12,and 18 months.RESULTS:Compared with the baseline amounts,serum creatinine decreased,and eGFR and creatinine clearance increased,significantly after intervention for 1,3,6,9,12,and 18 months(all P < 0.05).Mean eGFR increased by 2.11 mL/min per 1.73 m7 y after18-month treatment.Urinary protein at 24 h decreased significantly after 1,3,9,and 12 months(P < 0.05).Hb_(A1C) decreased significantly(P < 0.05) after 3,6,9,12,and 18 months,and systolic blood pressure decreased significantly(P < 0.05) after 1,3,and 6 months.Total cholesterol decreased significantly(P < 0.05) after 1,3,6,and 18 months.Triglyceride and low-density lipoprotein-cholesterol decreased significantly(P < 0.05) after 1 and 3 months.CONCLUSION:Shenzhuo formula can improve eGFR and possibly slow DKD progression.Shenzhuo formula can also lower Hb_(A1C),lipid levels and blood pressure. | Tian Jiaxing Zhao Linhua Zhou Qiang Liu Wenke Chen Xinyan Lian Fengmei Tong Xiaolin | 2015 | Journal of Traditional Chinese Medicine2015，35，5： | 8 |
| 3 | Dose-effect analysis of treatment by modified Zhibaidihuang decoction on polycystic ovary syndrome hyperandrogenism显示文摘OBJECTIVE: To observe the efficacy and safety of different dosages of modified Zhibaidihuang decoction(MZBDD) on polycystic ovary syndrome(PCOS) hyperandrogenism(HA) patients.METHODS: Ninety PCOS HA patients and 30 infertile patients due to tubal factor were selected. Ninety PCOS HA patients were randomly divided into three groups: low dosage group(LDG), medium dosage group(MDG) and high dosage group(HDG) and infertile patients were selected as normal control group(NCG). PCOS HA patients were treated with different dosage of MZBDD for 4 weeks. For HA patients, serum total testosterone(T), estrodial(E2), follicle stimulating hormone(FSH), luteinizing hormone(LH), prolatin(PRL), alanine aminotransferase(AST), aspartate amino transferase(AST) were determined before and after treatment, while acne scores(Rosenfield) were signed. Basal body temperatures(BBT) were asked to be measured every day. And for the else, T, E2,FSH, LH, PRL, AST, and AST were determined before treatment.RESULTS: Totally 111 patients completed the clinical research. There were no differences among the four groups on serum T before treatment(P =0.221). Serum T concentration of both MDG and HDG after treatment significantly were lower than that of before treatment(P = 0.039, P = 0.000),while there was no obvious difference in LDG(P =0.829). Serum T concentration of both MDG and HDG were significantly lower than that of LDG after treatment(P = 0.048, P = 0.006). To compared with before treatment, there were no differences in Serum FSH, LH, E2, P and PRL among the three groups(LDG, MDG, HDG)(as for FSH, P = 0.136, P = 0.503,P = 0.062; as for LH, P = 0.473, P = 0.513, P = 0.096;as for E2, P = 0.206, P = 0.927, P = 0.076; as for PRL,P = 0.120, P = 0.903, P = 0.407, as for P, P = 0.308, P =0.866, P = 0480). Acne scores of all the three groups were obviously lower than that of before treatment(P = 0.031; P = 0.033; P = 0.002). 39.5% of the patients had biphasic BBT, but there were no differences among the three groups(P = 0.510). There were no differences with ALT and AST between after and before treatment among the three groups(LDG, MDG, HDG)(as for ALT, P = 0.742, P = 0.383,P = 0.053; as for AST, P = 0.732, P = 0.519, P = 0.120).CONCLUSION: Different dosage of MZBDD has dose-effect relationship in treating PCOS HA. | Zhao Yiming Zheng Dongxue Cheng Ran Xu Xin Lian Fengmei Tong Xiaolin Liu Xinmin | 2018 | Journal of Traditional Chinese Medicine2018，38，2： | 4 |
| 4 | Shugan Jieyu capsule(舒肝解郁胶囊) improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial显示文摘OBJECTIVE: To evaluate the efficacy of the Shugan Jieyu capsule(舒肝解郁胶囊) on improving sleep and emotional disorder during Coronavirus disease 2019(COVID-19) convalescence. METHODS: We conducted a randomized, double-blind, placebo-controlled trial, and recruit 200 COVID-19 convalescence patients and then divide the subjects into two groups respectively: the experimental group(n = 100) and the control group(n = 100). Patients in the control group were given doses as a placebo, while those in the experimental group were given Shugan Jieyu capsule.The investigators mainly observed the differences between the two groups before and after treatment in terms of the rate of reduction and the rate of efficiency in Hamilton Depression Scale(HAMD-17) total scores from baseline, and recorded the scores of Hamilton Anxiety Scale(HAMA), Patient Health Questionnaire-15(PHQ-15), Insomnia Severity Index(ISI) and Treatment Emergent Symptom Scale at 2 week, the 4 week and the 6 week respectively after treatment, and compared the differences between the groups. And the occurrence of adverse events was recorded. RESULTS: After 6-week treatment, there were statistically significant differences in the rate of reduction as well as efficiency in HAMD-17 scores, HAMA Total Scores, PHQ-15 Score, ISI Score from baseline in the experimental group and control group(P < 0.05). There were 4 adverse events in the experimental group and 1 in the control group. CONCLUSION: Shugan Jieyu capsule could significantly improve sleep and emotional disorder in patients during COVID-19 convalescence. | AN Xuedong ZHANG Qing TAO Junxiu LI Li CHEN Yun LI Kejian HE Jing LIU Ru GUO Juan ZHANG Jia ZHU Hui LIAN Fengmei LI Xiaodong | 2022 | Journal of Traditional Chinese Medicine2022，42，5： | 2 |
| 5 | Chinese Herbal Medicine Tianqi Reduces Progression From Im- paired Glucose Tolerance to Diabetes: A Double-Blind, Randomized, Placebo-Controlled,Muhicenter Trial显示文摘 | Lian Fengmei Li Guangwei Chert Xinyan | 2014 | J Clin Endocrinol Metab2014，99，2： | 1 |
| 6 | Clinical Observations on the dose-effect relationship of gegen qin lian decoction on 54 out-patients with type 2 diabetes显示文摘 | Tong Xiaolin Zhao Linhua Lian Fengmei | | 0，，01： | 1 |
| 7 | Essential factors of Sui Zheng Shi Liang strategy in Type 2 diabetes treatment assessed by questionnaire显示文摘OBJECTIVE: Sui Zheng Shi Liang strategy (regulating prescription dosage with different syndromes) is an important part of syndrome differentiation and treatment in Traditional Chinese Medicine (TCM). Questionnaires were given to doctors and patients to study the essential factors (indicators and timing) of Sui Zheng Shi Liang strategy in the treatment process of type 2 diabetes (T2DM). METHODS: Two questionnaires were designed for diabetes patients and their doctors. The questionnaires included the most important indicators for determining the patient's condition, the ability of TCM in treating T2DM, the length of time it takes for TCM to be effective, and when to adjust the prescription dosage.The frequency of answers was calculated, summarized, and analyzed after the survey. RESULTS: Twenty questionnaires from doctors and 90 questionnaires from patients were included in the analysis. Doctors and patients recognized thatTCM could decrease blood glucose, improve syndromes, and delay complications. Doctors were mainly concerned about glycosylated hemoglobin, while the patients were concerned about fasting plasma glucose for determining whether treatment was effective. Doctors also paid attention to changes in blood sugar and syndromes 2 weeks after medication was given as the indication to adjust the prescription dosage, while patients were concerned about these factors in 4 weeks.The prescription should be regulated when there are side effects or the medication is ineffective. CONCLUSION: The essential factor in the treatment process of T2DM in Sui Zheng Shi Liang strategy is that if fasting blood glucose level did not decrease after 4 weeks of treatment, the Chinese medicine prescription should be adjusted. | Fengmei Lian Xinyan Chen Linhua Zhao Lipeng Xu Xiaolin Tong | 2013 | Journal of Traditional Chinese Medicine2013，33，1： | 0 |
| 8 | Effectiveness and safety of Jinshuibao capsules(金水宝胶囊)in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019:a pilot randomized,double-blind,placebo-controlled clinical trial显示文摘OBJECTIVE:To evaluate the effectiveness and safety of Jinshuibao capsules(金水宝胶囊),a Traditional Chinese Medicine(TCM),in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019(COVID-19)patients.METHODS:A total of 200 participants with COVID-19 in convalescence phase were randomly assigned into two groups at a 1:1 ratio in this multicenter randomized,double-blind,placebo-controlled trial.One group received Jinshuibao capsules,and the other received placebo.The patients were followed up at one and two weeks of treatment.Five symptoms(dry cough,shortness of breath,sweating,chest tightness and palpitation)improvement rates and full recovery rates were compared.RESULTS:All baseline characteristics were comparable between the two groups.After two weeks of treatment,symptom improvement rates for dry cough(74.00%vs 50.00%,P=0.015),shortness of breath(78.95%vs 46.15%,P<0.001),sweating(80.00%vs 57.75%,P=0.004),chest tightness(87.06%vs 60.47%,P<0.001)and palpitation(82.50%vs 64.56%,P=0.010)were significantly higher in the Jinshuibao group compared with the control group.Meanwhile,Jinshuibao capsules treatment also displayed more satisfactory full recovery rates of all five symptoms(dry cough 58.00%vs 19.57%,shortness of breath 18.95%vs 7.69%,sweating 36.00%vs 19.72%,chest tightness 32.94%vs 13.95%,and palpitation 48.75%vs 29.11%)in participants with COVID-19 in convalescence phase compared with the control group(P<0.05).No severe adverse events were reported in either group.CONCLUSIONS:Jinshuibao capsules have the potential to improve residual cardiopulmonary symptoms in convalescent COVID-19 patients,with few adverse events. | ZHANG Yuehong DONG Dandan YAN Youqin ZHANG Hao WANG Guangli ZHOU Wei LI Wei QIU Li LI Tingming LIU Quan XIA Ping MAO Lina YANG Danlin YANG Lu LIAN Fengmei TONG Xiaolin BA Yuanming | 2023 | Journal of Traditional Chinese Medicine2023，43，1： | 0 |
| 9 | Effectiveness of Xiangsha Liujun pills(香砂六君丸)on decreased digestive function in convalescent patients of coronavirus disease 2019:a randomized,double blind,placebo controlled clinical trial显示文摘OBJECTIVE:To evaluate the effectiveness and safety of Xiangsha Liujun pills(香砂六君丸) on the decreased digestive function in patients in the recovery phase of the Coronavirus disease 2019(COVID-19).METHODS:A randomized,double blind,placebo controlled clinical trial was conducted.A total of 200 COVID-19 patients in the recovery phase were included in our study in Ezhou Hospital of Traditional Chinese Medicine.Totally 200 subjects were randomly divided into a treatment group(Xiangsha Liujun pills) and a control group(placebo),with 100 in each group.Subjects took Xiangsha Liujun pills or placebo orally three times a day for two weeks.Three visits were scheduled at week 0(baseline),week 1(the middle of the intervention) and week 2(the end of the intervention) for each eligible patient.The total efficacy rates for improving the Traditional Chinese Medicine(TCM) symptoms(fatigue,poor appetite,abdominal distension and loose stools) and the disappearance rates of symptoms were observed and compared in the treatment and control groups.Adverse events were recorded during the study period.SAS 9.4 was used to analyze the data.RESULTS:A total of 200 patients were included in this study,among which 4 participants withdrew because the drugs did not work.Three patients were excluded for age.Before the treatment,there was no significant difference between the TCM symptoms scores of subjects.After 1 week of treatment,the full analysis set(FAS) showed that the efficacy rates for abdominal distension and loose stools in the treatment group were significantly higher than the control group(P < 0.05).There were no significant differences in the efficacy rates for fatigue and poor appetite between the two groups(P > 0.05).In addition,the disappearance rate of fatigue in the treatment group was significantly higher than the control group(P < 0.05);there were no significant differences between the two groups after treatment in the rates of poor appetite,abdominal distension,and loose stools(P > 0.05).After 2 weeks of treatment,the efficacy rates for fatigue,poor appetite,abdominal distension,and loose stools in the treatment group were significantly higher than the control group(P < 0.05).The disappearance rate of loose stools in the treatment group was significantly higher than the control group(P < 0.05).However,there were no significant differences in the disappearance rates of fatigue,poor appetite,and abdominal distension between the two groups(P > 0.05).No severe adverse events were reported by subjects during the study.CONCLUSIONS:This clinical study confirmed that Xiangsha Liujun pills can effectively improve the symptoms related to the decreased digestive function in COVID-19 convalescent patients. | ZHANG Yuehong SHAO Xianzhi ZHAO Qianlong ZHAN Hualong ZHANG Jianhua DU Sisi CHEN Jing LIU Yingfang ZHOU Haiwang CHEN Xinsheng HONG Ying LIAN Fengmei TONG Xiaolin BA Yuanming | 2023 | Journal of Traditional Chinese Medicine2023，43，3： | 0 |
| 10 | Effectiveness of Xiaoyao capsule(逍遥丸)on sleep disorders and mood disturbance in patients in recovery from coronavirus disease 2019:a randomized controlled trial显示文摘OBJECTIVE:To study the efficacy of Xiaoyao capsule(逍遥丸)in improving the clinical symptoms of sleep and mood disorders during recovery from coronavirus disease 2019(COVID-19).METHODS:The study cohort comprised 200 patients with sleep and mood disorders during recovery from COVID-19.Patients were randomized into the control group and the experimental group in a 1:1 ratio by blocked randomization.The patients received either Xiaoyao capsule(experimental group)or a placebo Xiaoyao capsule(control group)for 2 weeks.The improvements in the Traditional Chinese Medicine(TCM)syndrome scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep were compared between the two groups.RESULTS:The TCM syndrome pattern scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep did not significantly differ between the experimental group versus the control group in the full analysis set and the per protocol set after 1 and 2 weeks of treatment(P>0.05).CONCLUSIONS:Xiaoyao capsule do not significantly improve the clinical symptoms of sleep and mood disorders in patients in recovery from COVID-19. | YANG Cunqing LIAN Fengmei YANG Guiping HUANG Yufeng ZHANG Shuangbin WANG Jianghua ZHOU Jing GUO Dongqing SHEN Chuanyun YE Tiansong FU Aojie LI Xiaoli CHEN Le ZHANG Huifeng TU Qiyin WANG Ying YANG Wenzhe TONG Xiaolin BA Yuanming | 2023 | Journal of Traditional Chinese Medicine2023，43，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员